Subscribe to Entrepreneur for $5
Subscribe

Regeneron Says Antibodies Show Success in Preventing COVID-19 Infections

Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons.

By
This story originally appeared on The Epoch Times

Monoclonal antibodies that have already proven successful in preventing hospitalizations in people who contract COVID-19 may also serve as protection against COVID-19 infection, according to new data.

Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons.

The data comes from a phase three trial run by the company with the National Institute of Allergy and Infectious Diseases.

Researchers followed participants in the trial for eight months.

The trial already indicated the combination of the drugs casirivimab and imdevimab, together known as Regen-Cov, was successful in preventing COVID-19 infection in the month following administration.

The new data suggest the protection spans for over half a year.

“These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised,” Dr. Myron Cohen, who leads the monoclonal antibody research at the National Institutes of Health-sponsored COVID Prevention Network, said in a statement released by Regeneron.

SARS-CoV-2 is another name for the CCP (Chinese Communist Party) virus, which causes COVID-19.

While some participants who received the antibodies did contract the illness, none were hospitalized due to COVID-19, compared to six people in the placebo group, researchers said. None of the participants who were treated with the drugs died from COVID-19.

Some of the participants from both arms received COVID-19 vaccines after the first month, including about 34 percent of those in the treatment arm.

Early results from the trial were reported in the New England Journal of Medicine but the new results have not yet been published in a peer-reviewed publication.

“We intend to rapidly share these additional data with regulatory authorities to help those in most need of protection from COVID-19,” Dr. George Yancopoulos, president and chief scientific officer at Regeneron, said in a statement.

Drug regulators previously authorized Regeneron’s monoclonal antibody treatment, but only to treat people who already have COVID-19 and are not in the hospital or in a specific set of post-exposure settings. Former President Donald Trump took the drug in late 2020 after testing positive for COVID-19.

Dr. Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, said on Twitter that the results indicate the monoclonal antibodies “clearly work.”

“Seems they should/will have a role in outbreaks in nursing home or other congregate setting, even with vaccination,” he said. 

By Zachary Stieber

 

Zachary Stieber covers U.S. news, including politics and court cases. He started at The Epoch Times as a New York City metro reporter.

The Epoch Times

Written By

The Epoch Times is the fastest-growing independent news media in America. We are nonpartisan and dedicated to truthful reporting.

We are free from the influence of any government, corporation, or political party—this is what makes us different from other media organizations. Our goal is to bring our readers accurate information so they can form their own opinions about the most significant topics of our time.

We don’t follow the unhealthy trend of agenda-driven journalism prevalent in today’s media environment. Instead, we use our principles of Truth and Tradition as our guiding light. We highlight in our reporting the best of humanity, the valuable lessons of history, and traditions that are beneficial for society.

The Epoch Times was founded in the United States in the year 2000 in response to communist repression and censorship in China. Our founders, Chinese-Americans who themselves had fled communism, sought to create an independent media to bring the world uncensored and truthful information.

The Epoch Times has received numerous awards for our reporting and design, including from the New York Press Association, the Society of Professional Journalists, and the Society for News Design.

The Epoch Times’ media network currently covers 21 languages and 33 countries.